Back to Search
Start Over
Predicting the HbA1c level following glucose-lowering interventions in individuals with HbA1c-defined prediabetes: a post-hoc analysis from the randomized controlled PRE-D trial.
- Source :
- Endocrine (1355008X); Jul2023, Vol. 81 Issue 1, p67-76, 10p
- Publication Year :
- 2023
-
Abstract
- Purpose: To investigate whether the prediction of post-treatment HbA<subscript>1c</subscript> levels can be improved by adding an additional biomarker of the glucose metabolism in addition to baseline HbA<subscript>1c</subscript>. Methods: We performed an exploratory analysis based on data from 112 individuals with prediabetes (HbA<subscript>1c</subscript> 39–47 mmol) and overweight/obesity (BMI ≥ 25 kg/m<superscript>2</superscript>), who completed 13 weeks of glucose-lowering interventions (exercise, dapagliflozin, or metformin) or control (habitual living) in the PRE-D trial. Seven prediction models were tested; one basic model with baseline HbA<subscript>1c</subscript> as the sole glucometabolic marker and six models each containing one additional glucometabolic biomarker in addition to baseline HbA<subscript>1c</subscript>. The additional glucometabolic biomarkers included: 1) plasma fructosamine, 2) fasting plasma glucose, 3) fasting plasma glucose × fasting serum insulin, 4) mean glucose during a 6-day free-living period measured by a continuous glucose monitor 5) mean glucose during an oral glucose tolerance test, and 6) mean plasma glucose × mean serum insulin during the oral glucose tolerance test. The primary outcome was overall goodness of fit (R<superscript>2</superscript>) from the internal validation step in bootstrap-based analysis using general linear models. Results: The prediction models explained 46–50% of the variation (R<superscript>2</superscript>) in post-treatment HbA1c with standard deviations of the estimates of ~2 mmol/mol. R<superscript>2</superscript> was not statistically significantly different in the models containing an additional glucometabolic biomarker when compared to the basic model. Conclusion: Adding an additional biomarker of the glucose metabolism did not improve the prediction of post-treatment HbA<subscript>1c</subscript> in individuals with HbA<subscript>1c</subscript>-defined prediabetes. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1355008X
- Volume :
- 81
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Endocrine (1355008X)
- Publication Type :
- Academic Journal
- Accession number :
- 164078504
- Full Text :
- https://doi.org/10.1007/s12020-023-03384-w